{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:14:19Z","timestamp":1768349659347,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02125-3","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:21:27Z","timestamp":1759843287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Functional characterization of BRCA1 variants of unknown significance using homologous recombination repair assays"],"prefix":"10.1186","volume":"27","author":[{"given":"Paloma","family":"Mart\u00edn-Bejarano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Mar\u00eda","family":"S\u00e1nchez-Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9rez","family":"Jessica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Mart\u00edn-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario Vidal","family":"Tocino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogelio","family":"Gonz\u00e1lez-Sarmiento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Bel\u00e9n","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2125_CR1","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","volume":"28","author":"R Yoshida","year":"2021","unstructured":"Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer. 2021;28:1167\u201380.","journal-title":"Breast Cancer"},{"key":"2125_CR2","doi-asserted-by":"publisher","first-page":"531790","DOI":"10.3389\/fonc.2020.531790","volume":"10","author":"A Hodgson","year":"2020","unstructured":"Hodgson A, Turashvili G. Pathology of hereditary breast and ovarian cancer. Front Oncol. 2020;10:531790.","journal-title":"Front Oncol"},{"key":"2125_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-023-10790-w","volume":"23","author":"N Bassi","year":"2023","unstructured":"Bassi N, et al. Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays. BMC Cancer. 2023;23:1\u201313.","journal-title":"BMC Cancer"},{"issue":"3","key":"2125_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11154-007-9038-0","volume":"8","author":"AR Bradbury","year":"2007","unstructured":"Bradbury AR, Olopade OI. Genetic susceptibility to breast cancer. Rev Endo Metab Dis. 2007;8(3):255\u201367.","journal-title":"Rev Endo Metab Dis"},{"key":"2125_CR5","doi-asserted-by":"publisher","unstructured":"Garber JE, Offit K. Hereditary cancer predisposition syndromes. 2016;23:276\u201392. https:\/\/doi.org\/10.1200\/JCO.2005.10.042.","DOI":"10.1200\/JCO.2005.10.042"},{"key":"2125_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/ijms23010348","volume":"23","author":"H Yamamoto","year":"2021","unstructured":"Yamamoto H, Hirasawa A. Homologous recombination deficiencies and hereditary tumors. Int J Mol Sci. 2021;23:348.","journal-title":"Int J Mol Sci"},{"key":"2125_CR7","doi-asserted-by":"publisher","first-page":"1053035","DOI":"10.3389\/fonc.2022.1053035","volume":"12","author":"E De Paolis","year":"2023","unstructured":"De Paolis E, et al. Assessing the pathogenicity of BRCA1\/2 variants of unknown significance: relevance and challenges for breast cancer precision medicine. Front Oncol. 2023;12:1053035.","journal-title":"Front Oncol"},{"key":"2125_CR8","doi-asserted-by":"crossref","unstructured":"Adam F, Fluri M, Scherz A, Rabaglio M. Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study. BMC Med Genom. 2023;16.","DOI":"10.1186\/s12920-023-01437-7"},{"key":"2125_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/oncolo\/oyae149","volume":"29","author":"DC Pavlick","year":"2024","unstructured":"Pavlick DC, Frampton GM, Ross JR. Understanding variants of unknown significance and classification of genomic alterations. Oncologist. 2024;29:658\u201366.","journal-title":"Oncologist"},{"key":"2125_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jlb\/lsx038","volume":"4","author":"L Hoffman-Andrews","year":"2017","unstructured":"Hoffman-Andrews L. The known unknown: the challenges of genetic variants of uncertain significance in clinical practice. J Law Biosci. 2017;4:648\u201357.","journal-title":"J Law Biosci"},{"key":"2125_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10147-017-1182-2","volume":"23","author":"M Takaoka","year":"2018","unstructured":"Takaoka M, Miki Y. BRCA1 gene: function and deficiency. Int J Clin Oncol. 2018;23:36\u201344.","journal-title":"Int J Clin Oncol"},{"key":"2125_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/hmg\/ddi476","volume":"15","author":"JR Morris","year":"2006","unstructured":"Morris JR, et al. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet. 2006;15:599\u2013606.","journal-title":"Hum Mol Genet"},{"key":"2125_CR13","doi-asserted-by":"publisher","first-page":"8457","DOI":"10.1128\/MCB.24.19.8457-8466.2004","volume":"24","author":"LM Starita","year":"2004","unstructured":"Starita LM, et al. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol. 2004;24:8457\u201366.","journal-title":"Mol Cell Biol"},{"key":"2125_CR14","doi-asserted-by":"crossref","unstructured":"Williams RS, Lee MS, Hau DD, Glover J. N. M. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nature Structural & Molecular Biology 2004 11:6 11, 519\u2013525 (2004).","DOI":"10.1038\/nsmb776"},{"key":"2125_CR15","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1074\/jbc.M210019200","volume":"278","author":"RS Williams","year":"2003","unstructured":"Williams RS, Glover JNM. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J Biol Chem. 2003;278:2630\u20135.","journal-title":"J Biol Chem"},{"key":"2125_CR16","doi-asserted-by":"publisher","first-page":"53007","DOI":"10.1074\/jbc.M310182200","volume":"278","author":"RS Williams","year":"2003","unstructured":"Williams RS, et al. Detection of protein folding defects caused by BRCA1-BRCT Truncation and missense mutations. J Biol Chem. 2003;278:53007\u201316.","journal-title":"J Biol Chem"},{"key":"2125_CR17","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1158\/0008-5472.CAN-09-4563","volume":"70","author":"MS Lee","year":"2010","unstructured":"Lee MS, et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res. 2010;70:4880.","journal-title":"Cancer Res"},{"key":"2125_CR18","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/2159-8290.CD-13-0094","volume":"3","author":"P Bouwman","year":"2013","unstructured":"Bouwman P, et al. A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov. 2013;3:1142\u201355.","journal-title":"Cancer Discov"},{"key":"2125_CR19","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/npjgenmed.2016.1","volume":"1","author":"NT Woods","year":"2016","unstructured":"Woods NT, et al. Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance. NPJ Genom Med. 2016;1:16001.","journal-title":"NPJ Genom Med"},{"key":"2125_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1534\/genetics.115.175802","volume":"200","author":"LM Starita","year":"2015","unstructured":"Starita LM, et al. Massively parallel functional analysis of BRCA1 RING domain variants. Genetics. 2015;200:413\u201322.","journal-title":"Genetics"},{"key":"2125_CR21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1158\/0008-5472.CAN-09-2850","volume":"70","author":"DJR Ransburgh","year":"2010","unstructured":"Ransburgh DJR, Chiba N, Ishioka C, Toland AE, Parvin JD. Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. Cancer Res. 2010;70:988\u201395.","journal-title":"Cancer Res"},{"issue":"12","key":"2125_CR22","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/ejhg.2014.40","volume":"22","author":"AY Steffensen","year":"2014","unstructured":"Steffensen AY et al. Functional characterization of BRCA1 gene variants by mini-gene splicing assay. Eur J Hum Genet. 2014;22(12):1362\u201368 (2014).","journal-title":"Eur J Hum Genet"},{"key":"2125_CR23","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1093\/hmg\/ddw094","volume":"25","author":"M de la Hoya","year":"2016","unstructured":"de la Hoya M, et al. Combined genetic and splicing analysis of BRCA1 c.[594-2A\u2009>\u2009C; 641A\u2009>\u2009G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Hum Mol Genet. 2016;25:2256\u201368.","journal-title":"Hum Mol Genet"},{"key":"2125_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/onc.2011.271","volume":"31","author":"Z Kais","year":"2012","unstructured":"Kais Z, Chiba N, Ishioka C, Parvin JD. Functional differences among BRCA1 missense mutations in the control of centrosome duplication. Oncogene. 2012;31:799\u2013804.","journal-title":"Oncogene"},{"key":"2125_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/humu.22251","volume":"34","author":"WI Towler","year":"2012","unstructured":"Towler WI, et al. Analysis of BRCA1 variants in Double-Strand break repair by homologous recombination and Single-Strand annealing. Hum Mutat. 2012;34:439.","journal-title":"Hum Mutat"},{"key":"2125_CR26","unstructured":"HCC1937, -. CRL-2336 | ATCC. https:\/\/www.atcc.org\/products\/crl-2336"},{"key":"2125_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/cancers16040741","volume":"16","author":"TG Meijer","year":"2024","unstructured":"Meijer TG, et al. Functional homologous recombination (HR) screening shows the majority of BRCA1\/2-Mutant breast and ovarian cancer cell lines are HR-Proficient. Cancers (Basel). 2024;16:741.","journal-title":"Cancers (Basel)"},{"key":"2125_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/cancers11020151","volume":"11","author":"L Caleca","year":"2019","unstructured":"Caleca L, et al. GFP-Fragment reassembly screens for the functional characterization of variants of uncertain significance in protein interaction domains of the BRCA1 and BRCA2 genes. Cancers (Basel). 2019;11:151.","journal-title":"Cancers (Basel)"},{"key":"2125_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10549-011-1599-7","volume":"129","author":"RD Brand\u00e3o","year":"2011","unstructured":"Brand\u00e3o RD, Van Roozendaal K, Tserpelis D, Garc\u00eda EG, Blok MJ. Characterisation of unclassified variants in the BRCA1\/2 genes with a putative effect on splicing. Breast Cancer Res Treat. 2011;129:971\u201382.","journal-title":"Breast Cancer Res Treat"},{"key":"2125_CR30","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/humu.23818","volume":"40","author":"MT Parsons","year":"2019","unstructured":"Parsons MT, et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: an ENIGMA resource to support clinical variant classification. Hum Mutat. 2019;40:1557.","journal-title":"Hum Mutat"},{"key":"2125_CR31","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/15592294.2015.1111504","volume":"10","author":"KJ Flower","year":"2016","unstructured":"Flower KJ, et al. DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer. Epigenetics. 2016;10:1121.","journal-title":"Epigenetics"},{"key":"2125_CR32","first-page":"332","volume":"BRCA1","author":"KP Pennington","year":"2012","unstructured":"Pennington KP, et al. TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 119. 2012;BRCA1:332.","journal-title":"Cancer 119"},{"key":"2125_CR33","doi-asserted-by":"publisher","first-page":"e21350","DOI":"10.7554\/eLife.21350","volume":"6","author":"RW Anantha","year":"2017","unstructured":"Anantha RW, et al. Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. Elife. 2017;6:e21350.","journal-title":"Elife"},{"key":"2125_CR34","doi-asserted-by":"publisher","first-page":"10086","DOI":"10.1038\/ncomms10086","volume":"6","author":"C Lu","year":"2015","unstructured":"Lu C, et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015;6:10086.","journal-title":"Nat Commun"},{"key":"2125_CR35","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1073\/pnas.0237285100","volume":"100","author":"MA Fleming","year":"2003","unstructured":"Fleming MA, Potter JD, Ramirez CJ, Ostrander GK, Ostrander EA. Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc Natl Acad Sci USA. 2003;100:1151.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2125_CR36","first-page":"e13553","volume":"13","author":"V Moorthy","year":"2021","unstructured":"Moorthy V, Sanku K, Singh HP, Khillan R, Patel PP. Cutaneous squamous cell carcinoma in lynch syndrome\u2014an overlooked association. Cureus. 2021;13:e13553.","journal-title":"Cureus"},{"key":"2125_CR37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10549-011-1661-5","volume":"132","author":"M Men\u00e9ndez","year":"2012","unstructured":"Men\u00e9ndez M, et al. Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat. 2012;132:979\u201392.","journal-title":"Breast Cancer Res Treat"},{"key":"2125_CR38","doi-asserted-by":"publisher","first-page":"e61302","DOI":"10.1371\/journal.pone.0061302","volume":"8","author":"F Quiles","year":"2013","unstructured":"Quiles F, et al. Functional and structural analysis of C-terminal BRCA1 missense variants. PLoS ONE. 2013;8:e61302.","journal-title":"PLoS ONE"},{"issue":"7726","key":"2125_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","volume":"562","author":"GM Findlay","year":"2018","unstructured":"Findlay GM et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature 2018;562(7726):217\u201322 (2018).","journal-title":"Nature"},{"key":"2125_CR40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/bs.apcsb.2022.02.003","volume":"130","author":"D Thirumal Kumar","year":"2022","unstructured":"Thirumal Kumar D, et al. Computational structural assessment of breast cancer type 1 susceptibility protein (BRCA1) and BRCA1-Associated ring domain protein 1 (BARD1) mutations on the protein-protein interface. Adv Protein Chem Struct Biol. 2022;130:375\u201397.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"2125_CR41","doi-asserted-by":"publisher","first-page":"5646","DOI":"10.1073\/pnas.0836054100","volume":"100","author":"PS Brzovic","year":"2003","unstructured":"Brzovic PS, et al. Binding and recognition in the assembly of an active BRCA1\/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci USA. 2003;100:5646\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2125_CR42","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ajhg.2018.07.016","volume":"103","author":"LM Starita","year":"2018","unstructured":"Starita LM, et al. A multiplex Homology-Directed DNA repair assay reveals the impact of more than 1,000 BRCA1 missense substitution variants on protein function. Am J Hum Genet. 2018;103:498.","journal-title":"Am J Hum Genet"},{"key":"2125_CR43","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ajhg.2022.01.019","volume":"109","author":"AI Adamovich","year":"2022","unstructured":"Adamovich AI, et al. The functional impact of BRCA1 BRCT domain variants using multiplexed DNA double-strand break repair assays. Am J Hum Genet. 2022;109:618.","journal-title":"Am J Hum Genet"},{"key":"2125_CR44","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4161\/cbt.1.5.165","volume":"1","author":"MA Carvalho","year":"2002","unstructured":"Carvalho MA, et al. Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation. Cancer Biol Ther. 2002;1:502\u20138.","journal-title":"Cancer Biol Ther"},{"key":"2125_CR45","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1158\/0008-5472.CAN-20-2723","volume":"81","author":"TK Foo","year":"2021","unstructured":"Foo TK, et al. ATR\/ATM-mediated phosphorylation of BRCA1 T1394 promotes homologous recombinational repair and G2\/M checkpoint maintenance. Cancer Res. 2021;81:4676.","journal-title":"Cancer Res"},{"key":"2125_CR46","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.3390\/cancers14153661","volume":"14","author":"D Berardi","year":"2022","unstructured":"Berardi D, et al. The differential metabolic signature of breast cancer cellular response to Olaparib treatment. Cancers (Basel). 2022;14:3661.","journal-title":"Cancers (Basel)"},{"key":"2125_CR47","doi-asserted-by":"publisher","first-page":"694793","DOI":"10.3389\/fonc.2021.694793","volume":"11","author":"A Gajan","year":"2021","unstructured":"Gajan A, et al. Analysis of adaptive Olaparib resistance effects on cisplatin sensitivity in triple negative breast cancer cells. Front Oncol. 2021;11:694793.","journal-title":"Front Oncol"},{"key":"2125_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/978-1-61779-998-3_27","volume":"920","author":"A Gunn","year":"2012","unstructured":"Gunn A, Stark JM. I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks. Methods Mol Biol. 2012;920:379\u201391.","journal-title":"Methods Mol Biol"},{"key":"2125_CR49","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1158\/1078-0432.CCR-14-0571","volume":"20","author":"KAT Naipal","year":"2014","unstructured":"Naipal KAT, et al. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res. 2014;20:4816\u201326.","journal-title":"Clin Cancer Res"},{"key":"2125_CR50","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ccr.2011.11.014","volume":"20","author":"R Drost","year":"2011","unstructured":"Drost R, et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell. 2011;20:797\u2013809.","journal-title":"Cancer Cell"},{"key":"2125_CR51","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10549-007-9868-1","volume":"112","author":"MD Miramar","year":"2008","unstructured":"Miramar MD, et al. Genetic analysis of BRCA1 and BRCA2 in breast\/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1. Breast Cancer Res Treat. 2008;112:353\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"2125_CR52","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10689-017-9985-x","volume":"16","author":"X Gabald\u00f3 Barrios","year":"2017","unstructured":"Gabald\u00f3 Barrios X, et al. Molecular characterization and clinical interpretation of BRCA1\/BRCA2 variants in families from murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical\u2013pathological features in BRCA carriers and non-carriers. Fam Cancer. 2017;16:477\u201389.","journal-title":"Fam Cancer"},{"key":"2125_CR53","doi-asserted-by":"publisher","first-page":"74233","DOI":"10.18632\/oncotarget.18815","volume":"8","author":"C Alvarez","year":"2017","unstructured":"Alvarez C, et al. BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. Oncotarget. 2017;8:74233.","journal-title":"Oncotarget"},{"key":"2125_CR54","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-20-0255","volume":"26","author":"P Bouwman","year":"2020","unstructured":"Bouwman P, et al. Functional categorization of BRCA1 variants of uncertain clinical significance in homologous recombination repair complementation assays. Clin Cancer Res. 2020;26:4559\u201368.","journal-title":"Clin Cancer Res"},{"key":"2125_CR55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13073-021-00976-x","volume":"13","author":"A Billaud","year":"2021","unstructured":"Billaud A, et al. Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes. Genome Med. 2021;13:174.","journal-title":"Genome Med"},{"key":"2125_CR56","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.1209909","volume":"334","author":"R Shakya","year":"2011","unstructured":"Shakya R, et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science. 2011;334:525\u20138.","journal-title":"Science"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02125-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02125-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02125-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:22:38Z","timestamp":1759846958000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-02125-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2125"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02125-3","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}